Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18285457 | 1.00 | OPRD1 (0.42) | OPRD1APPHTR1AADRA2ADRD2 | |
| SCHEMBL18645202 | 0.84 | ACKR3 (0.46) | GPR119KDM1AALOX5APFEN1 | |
| SCHEMBL18285464 | 0.82 | CUL4A (0.39) | ALDH1A1GPR119LMNAMEN1KMT2A | |
| SCHEMBL18285483 | 0.81 | MEN1 (0.40) | OPRD1APPHTR1AADRA2ADRD2 | |
| SCHEMBL18285485 | 0.81 | MEN1 (0.40) | OPRD1APPHTR1AADRA2ADRD2 | |
| SCHEMBL15575473 | 0.79 | KMT2A (0.50) | OPRD1APPHTR1AADRA2ADRD2 | |
| SCHEMBL15056676 | 0.79 | PRMT5 (0.49) | OPRD1APPHTR1AADRA2ADRD2 | |
| SCHEMBL15056678 | 0.79 | PRMT5 (0.49) | OPRD1APPHTR1AADRA2ADRD2 | |
| SCHEMBL23450730 | 0.77 | ANO1 (0.44) | ALDH1A1LMNA | |
| SCHEMBL30111808 | 0.77 | ANO1 (0.44) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3912979-B1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20250197402-A1 | Tyrosine Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2025-06-19 | — | — | US | disclosed |
| CN-113149983-B | Tyrosine kinase inhibitors | 普林斯匹亚生物制药公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20230151012-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2023-05-18 | — | — | US | disclosed |
| EP-4112618-A1 | TYROSINE KINASE INHIBITORS | Principia Biopharma Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| EP-3912979-A1 | TYROSINE KINASE INHIBITORS | Principia Biopharma Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| CN-113149983-A | Tyrosine kinase inhibitors | 普林斯匹亚生物制药公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20210171526-A1 | Tyrosine Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2021-06-10 | — | — | US | disclosed |
| EP-3303334-B1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2021-06-02 | — | — | EP | disclosed |
| CN-106459049-B | Tyrosine kinase inhibitors | 普林斯匹亚生物制药公司 | 2020-11-27 | — | — | CN | disclosed |
| US-20180162861-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2018-06-14 | — | — | US | disclosed |
| EP-3303334-A1 | TYROSINE KINASE INHIBITORS | Principia Biopharma Inc. (US) | 2018-04-11 | — | — | EP | disclosed |
| US-9688676-B2 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170129890-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2017-05-11 | — | — | US | disclosed |
| WO-2016196840-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171526-A1 | Tyrosine Kinase Inhibitors | BTK, LYN, SYK | OPRD1 4744/4885APP 4459/4885HTR1A 4775/4885 |
| US-20180162861-A1 | TYROSINE KINASE INHIBITORS | BTK, LYN, SYK | OPRD1 4744/4885APP 4459/4885HTR1A 4775/4885 |
| US-20170129890-A1 | TYROSINE KINASE INHIBITORS | BTK, LYN, SYK | OPRD1 4744/4885APP 4459/4885HTR1A 4775/4885 |
| US-20230151012-A1 | TYROSINE KINASE INHIBITORS | BTK, LYN, SYK | OPRD1 4744/4885APP 4459/4885HTR1A 4775/4885 |
| US-20250197402-A1 | Tyrosine Kinase Inhibitors | BTK, LYN, SYK | OPRD1 4744/4885APP 4459/4885HTR1A 4775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.